Literature DB >> 30847179

Longer survival in patients with metastatic uterine leiomyosarcoma treated with trabectedin: A case report.

Théophraste Henry1, Elizabeth Fabre2, Laurent S Baccar3, Michele Lamuraglia4,5.   

Abstract

Trabectedin (ET-743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata, with a chemical structure characterized by three fused tetrahydroisoquinoline rings. In the present case report, two patients with advanced and metastatic uterine leiomyosarcomas (ULMS) with significant progression-free survival (PFS) and overall survival (OS) administered Trabectedin as second and third line treatment are reported. The first case received third line Trabectedin with a PFS of 24 months and an OS of 35 months. The second case received second line Trabectedin with a PFS of 24 months and an OS of 30 months. In addition, a good safety record was obtained in the long-term administration of Trabectedin (more so in case 1 than case 2), with a good quality of life.

Entities:  

Keywords:  Trabectedin; chemotherapy; leiomyosarcoma; metastasis; uterine

Year:  2019        PMID： 30847179      PMCID： PMC6388506          DOI： 10.3892/mco.2019.1797

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN： 2049-9450


  9 in total

Review 1.  Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years.

Authors:  N Penel; M Van Glabbeke; S Marreaud; M Ouali; J Y Blay; P Hohenberger
Journal:  Ann Oncol       Date:  2010-12-23       Impact factor: 32.976

Review 2.  Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.

Authors:  A A Gupta; X Yao; S Verma; H Mackay; L Hopkins
Journal:  Clin Oncol (R Coll Radiol)       Date:  2013-01-05       Impact factor: 4.126

3.  Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis.

Authors:  Emanuela D'Angelo; Inigo Espinosa; Rola Ali; C Blake Gilks; Matt van de Rijn; Cheng-Han Lee; Jaime Prat
Journal:  Gynecol Oncol       Date:  2011-02-12       Impact factor: 5.482

4.  Chemotherapy (gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) in inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a clinical practice guideline.

Authors:  A A Gupta; X Yao; S Verma; H Mackay; L Hopkins
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

5.  Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.

Authors:  Patricia Pautier; Anne Floquet; Christine Chevreau; Nicolas Penel; Cécile Guillemet; Corinne Delcambre; Didier Cupissol; Frédéric Selle; Nicolas Isambert; Sophie Piperno-Neumann; Antoine Thyss; François Bertucci; Emmanuelle Bompas; Jerôme Alexandre; Olivier Collard; Sandrine Lavau-Denes; Patrick Soulié; Maud Toulmonde; Axel Le Cesne; Benjamin Lacas; Florence Duffaud
Journal:  Lancet Oncol       Date:  2015-03-18       Impact factor: 41.316

6.  Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.

Authors:  Robert L Giuntoli; Daniel S Metzinger; Connie S DiMarco; Stephen S Cha; Jeff A Sloan; Gary L Keeney; Bobbie S Gostout
Journal:  Gynecol Oncol       Date:  2003-06       Impact factor: 5.482

7.  A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.

Authors:  Bradley J Monk; John A Blessing; Daron G Street; Carolyn Y Muller; James J Burke; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2011-10-13       Impact factor: 5.482

8.  Trends in survival for patients with metastatic soft-tissue sarcoma.

Authors:  Antoine Italiano; Simone Mathoulin-Pelissier; Axel Le Cesne; Philippe Terrier; Sylvie Bonvalot; Françoise Collin; Jean-Jacques Michels; Jean-Yves Blay; Jean-Michel Coindre; Binh Bui
Journal:  Cancer       Date:  2010-10-13       Impact factor: 6.860

9.  Comparison of the diagnostic accuracy of contrast-enhanced MRI and diffusion-weighted MRI in the differentiation between uterine leiomyosarcoma / smooth muscle tumor with uncertain malignant potential and benign leiomyoma.

Authors:  Gigin Lin; Lan-Yan Yang; Yu-Ting Huang; Koon-Kwan Ng; Shu-Hang Ng; Shir-Hwa Ueng; Angel Chao; Tzu-Chen Yen; Ting-Chang Chang; Chyong-Huey Lai
Journal:  J Magn Reson Imaging       Date:  2015-09-18       Impact factor: 4.813
  9 in total
  1 in total

1.  Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO).

Authors:  María Jesús Rubio; María José Lecumberri; Silvia Varela; Jesús Alarcón; María Eugenia Ortega; Lydia Gaba; Jaime Espinós; Julia Calzas; Pilar Barretina; Isabel Ruiz; Gloria Marquina; Ana Santaballa
Journal:  Gynecol Oncol Rep       Date:  2020-06-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.